ピペラシリン・タゾバクタム誘発性白血球減少症のリスク因子特定のためのLassoモデルの適用
Jiheng Liu1, Xuefeng Yuan2, Xiaohui Liu3
1Department of Hematology & Oncology, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China.
Objective:
We conducted a retrospective study to investigate the prevalence, clinical characteristics, and risk factors for leukopenia in patients receiving piperacillin-tazobactam (TZP) therapy.
Methods:
This observational study was conducted from January to December 2022 at a tertiary general hospital in China. All patients over 18 years old who received TZP for more than 48 hours were included. Patients were stratified into adverse drug reactions (ADR) (n=41, TZP-induced leukopenia or neutropenia) and Control (n=8014, no ADR) groups. To balance covariates, 1:2 propensity score matching (PSM) was applied using age, infection type, gender, and comorbidity index, resulting in 82 matched controls for comparative analysis. We employed least absolute shrinkage and selection operator (LASSO) regression to identify risk factors for TZP-induced leukopenia.
Results:
A total of 123 patients were analyzed. The average duration of treatment was 10 days (IQR: 7, 19). In 41 patients with TZP-induced leukopenia, the mean onset time was 17.7 ± 6.6 days. Among these, 29 (70.7%) developed neutropenia (including 1 severe case), and 3 (7.3%) had drug-induced fever. Therapy duration (odds ratio (OR) = 1.53, 95% confidence interval (CI) 1.32-1.76) was identified as a significant influencing factor for leukopenia caused by TZP through the LASSO regression screening process.
Conclusion:
Clinicians should recognize the potential association between TZP administration and leukopenia. Routine hematologic monitoring should emphasize leukocyte trends to assess both therapeutic response and drug safety.
